Helex

Helex is a biotechnology company developing next-generation gene-editing therapies for genetic kidney diseases, starting with Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company's proprietary lipid nanoparticle technology enables targeted delivery of therapeutic cargo to the kidney, while its pioneering Epic-Cure technology ensures de-risked drug design for greater precision and safety of genetic medicines by avoiding unwanted editing in non-target cells and tissues. Helex leverages data, machine learning, and epigenetics to reduce trial and error in designing gene editing-based drugs, targeting over 700 million people worldwide suffering from chronic kidney disease. The company has been recognized by NIH as a winner of Phase 2 of the TARGETED Genome Editor Delivery Challenge and has presented at ASN Kidney Week, ESGCT Annual Meeting, and ASGCT. Founded in 2021 and headquartered in New York City with operations in Hyderabad, India, Helex has raised $6M in seed funding from investors including IndieBio, Bluehill VC, pi Ventures, and SOSV.